Quantitative systems pharmacology for rare disease drug development

• Published in: Journal of pharmaceutical sciences 2023-09, Vol.112 (9), p.2313-2320
• Main Authors: Bai, Jane PF, Wang, Jie, Zhang, Yifei, Wang, Lingshan, Jiang, Xiling
• Format: Article
• Language: English
• Subjects: Dose optimization; Quantitative systems pharmacology; Rare disease drug development
• ISSN: 0022-3549; 1520-6017
• DOI: 10.1016/j.xphs.2023.06.019

Though hundreds of drugs have been approved by the US Food and Drug Administration (FDA) for treating various rare diseases, most rare diseases still lack FDA-approved therapeutics. To identify the opportunities for developing therapies for these diseases, the challenges of demonstrating the efficacy and safety of a drug for treating a rare disease are highlighted herein. Quantitative systems pharmacology (QSP) has increasingly been used to inform drug development; our analysis of QSP submissions received by FDA showed that there were 121 submissions as of 2022, for informing rare disease drug development across development phases and therapeutic areas. Examples of published models for inborn errors of metabolism, non-malignant hematological disorders, and hematological malignancies were briefly reviewed to shed light on use of QSP in drug discovery and development for rare diseases. Advances in biomedical research and computational technologies can potentially enable QSP simulation of the natural history of a rare disease in the context of its clinical presentation and genetic heterogeneity. With this function, QSP may be used to conduct in-silico trials to overcome some of the challenges in rare disease drug development. QSP may play an increasingly important role in facilitating development of safe and effective drugs for treating rare diseases with unmet medical needs.